Thus, we established a simple score scale composed of serum CRP, IL-6 and TNF-α levels to estimate the risk for progressing to PsA among psoriasis vulgaris patients, and validated the scale internally and for a retrospective cohort. The gene discussed is IL6; the disease is psoriasis vulgaris.